AU Patent

AU2024201828B2 — Methods of treating and/or preventing actinic keratosis

Assigned to Atnx Spv LLC United States · Expires 2026-02-19 · 0y expired

What this patent protects

This disclosure relates to methods of treating and preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01 to a subject in need thereof. In particular, the therapeutically effective amount of KX-01 is from about 0.1 mg to about 10 mg.

USPTO Abstract

This disclosure relates to methods of treating and preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01 to a subject in need thereof. In particular, the therapeutically effective amount of KX-01 is from about 0.1 mg to about 10 mg.

Drugs covered by this patent

oxymetazoline-hydrochloride (OXYMETAZOLINE HYDROCHLORIDE)

Patent Metadata

Patent number: AU2024201828B2
Jurisdiction: AU
Classification: —
Expires: 2026-02-19
Drug substance claim: No
Drug product claim: No
Assignee: Atnx Spv LLC United States
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.